Trelagliptin succinate A tert-Butyl ester Chemical Name: 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2

Chemical Name: 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2

physostigmine

Formula: C25H26FN3O7S

LY-2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts

LY3009120 showed activities against BRaf or Ras mutant tumor cells

Trelagliptin succinate A tert-Butyl ester Chemical Name: 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2Trelagliptin, also known as SYR 472, is a long acting dipeptidyl peptidase 4 (DPP 4) inhibitor that is being developed by Takeda for the treatment of type 2 diabetes (T2D). Once weekly SYR 472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease. Trelagliptin (Zafatek()) was approved in